10-Q: Y-mAbs Q2 2025: Merger Deal, Narrowed Loss, DANYELZA Sales Dip

Y-mAbs Therapeutics reported a narrowed net loss in Q2 2025, driven by reduced operating expenses, but saw a decline in DANYELZA product revenue, while announcing a definitive merger agreement at $8.60 per share.

Summary

• Net loss for the three months ended June 30, 2025, significantly narrowed to $3.2 million, a 65% improvement from $9.2 million in the same period last year.
• Net loss for the six months ended June 30, 2025, improved to $8.4 million, a 47% improvement from $15.9 million in the prior year period.
• Total revenues for the three months ended June 30, 2025, decreased by 14% to $19.5 million, primarily due to a 17% decline in net product revenue from DANYELZA sales.
• Total revenues for the six months ended June 30, 2025, decreased by 5% to $40.4 million, driven by an 18% decline in U.S. net product revenue for DANYELZA.
• Operating expenses decreased by 24% for the three-month period and 14% for the six-month period, largely due to reduced selling, general, and administrative expenses (including lower litigation settlements and legal expenses) and a decrease in research and development costs.
• Cash and cash equivalents stood at $62.3 million as of June 30, 2025, down from $67.2 million at December 31, 2024.
• Net cash used in operating activities increased by 65% to $5.3 million for the six months ended June 30, 2025, compared to $3.2 million in the prior year period.
• The company entered into a definitive Merger Agreement on August 4, 2025, to be acquired by Perseus BidCo US, Inc. for $8.60 per share in cash.

Sentiment

Score: 6

Explanation: While operational results are mixed with declining revenue but narrowed losses due to cost cuts, the definitive merger agreement at a fixed price of $8.60 per share provides a clear exit strategy and valuation for shareholders, significantly de-risking the investment for those holding shares below the offer price. The merger agreement is the most impactful news, overshadowing the mixed quarterly financials.

Positives

• Net loss significantly narrowed by 65% for the three-month period and 47% for the six-month period, indicating improved cost management.
• Selling, general, and administrative expenses decreased substantially by 34% for the quarter and 15% for the six-month period, partly due to lower litigation-related costs.
• Research and development expenses decreased by 10% for the quarter and 12% for the six-month period, reflecting the business realignment strategy.
• Interest and other income increased significantly by 271% for the quarter and 245% for the six-month period, primarily due to foreign currency transactional gains.
• The definitive merger agreement at $8.60 per share provides a clear valuation and potential liquidity event for shareholders.
• DANYELZA's Phase 2 osteosarcoma trial (Study 15-096) showed a 12-month event-free survival (EFS) of 36% overall and 50% for patients with 4+ staining intensity GD2 expression, which is considered compelling compared to the typical standard of care EFS of approximately 20%.
• The GD2-SADA Phase 1 clinical trial has been well-tolerated across multiple dose cohorts with no dose-limiting toxicities or treatment-related serious adverse events reported.

Negatives

• Net product revenue from DANYELZA decreased by 17% for the three-month period and 5% for the six-month period, primarily due to declining patient volume in the U.S. and absence of stocking orders from Western Europe and Eastern Asia.
• Net cash used in operating activities increased by 65% to $5.3 million for the six months ended June 30, 2025, indicating higher cash burn.
• The DANYELZA osteosarcoma trial (Study 15-096) missed its established primary endpoint of 40% 12-month event-free survival.
• The planned transition of DANYELZA manufacturing to a new facility in Italy in the second half of 2026 is expected to result in higher production costs and inventory levels, with no production during the transition period.

Risks

• The Merger with Perseus BidCo US, Inc. may not be completed within the anticipated timeframe or at all, which could adversely affect the company's business, prospects, financial condition, and results of operations.
• The pendency of the Merger could cause substantial disruptions, create uncertainty, and adversely affect the company's business, financial results, and operations, including employee retention and relationships with partners.
• While the Merger Agreement is in effect, the company is subject to restrictions on its business activities, limiting its ability to pursue strategic opportunities or respond to competitive pressures.
• The company may be required to pay a termination fee of $14.25 million to Parent if the Merger Agreement is terminated under certain specified circumstances.
• Litigation may arise in connection with the Merger, which could be costly, divert management's attention, and harm the business.
• The company's ability to use its net operating loss carryforwards and certain other tax attributes may be limited due to an anticipated ownership change upon the closing of the Merger.
• New tax laws, such as the One Big Beautiful Bill Act enacted on July 4, 2025, could adversely affect the business, cash flow, financial condition, or results of operations.
• Macroeconomic conditions, including tariffs and escalating trade tensions, and geopolitical events, could adversely affect the company's business, financial condition, and results of operations, particularly given its global operations and supply chain.
• Reliance on a small number of third-party contract manufacturing organizations (CMOs) for DANYELZA and product candidates poses a risk, as finding suitable replacements is difficult and the manufacturing transition to a new facility may not be successful or timely.
• The SADA PRIT technology has not been approved for commercial use by the FDA or any other regulatory authority, and clinical efforts may not result in approval or marketable products.
• The company relies on exclusive rights with Memorial Sloan Kettering Cancer Center (MSK) and Massachusetts Institute of Technology (MIT), and failure to meet conditions could lead to license cancellation.
• The company will require additional funding to finance operations, complete development, and commercialization if the Merger is not consummated, and sufficient funds may not be available on attractive terms or at all.

Future Outlook

The company expects net operating losses to continue until DANYELZA product revenue provides sufficient funds to cover significant research and development expenses. Research and development expenses are projected to remain consistent in 2025 compared to 2024. A manufacturing transition for DANYELZA drug product from North Carolina to Italy is anticipated in the second half of 2026, which is expected to result in higher production costs and inventory levels, with no production during the transition period. If the merger is not consummated, the company estimates its current cash and cash equivalents will be sufficient to fund operations into 2028, but acknowledges the need for additional funding through various sources.

Management Comments

• Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.
• We believe that this data shows DANYELZA’s potential to serve a high unmet need within osteosarcoma where survival rates have shown little or no improvement in decades.
• We also believe that the data supporting the use of DANYELZA for targeting GD2 is very compelling and worth further development.
• We are considering the advancement of a diagnostic tool for GD2, which could prove to be a valuable tool for a potential pivotal trial in this or other GD2 related indications.
• We believe SADA PRIT Technology could potentially improve the efficacy of immunological therapeutics, e.g., naked monoclonal antibodies, in tumors that have not historically demonstrated meaningful responses to immunological agents.
• We expect that the manufacturer of the DANYELZA drug product will transition the manufacturing from its facility in Greenville, North Carolina, to a facility in Monza, Italy and that no DANYELZA drug product will be manufactured from the date manufacturing ceases in Greenville, North Carolina, which is estimated to be in the second half of 2026, until the new facility becomes FDA approved to produce and begin production of the DANYELZA drug product.
• We expect to experience higher production costs and inventory levels with respect to drug product produced for the planned transition.
• We estimate that our cash and cash equivalents will be sufficient to fund operations as currently planned into 2028.

Industry Context

The company operates in the highly competitive and rapidly evolving biopharmaceutical and oncology sectors, focusing on advanced cancer treatments like radioimmunotherapy and antibody-based therapies. Its strategic business realignment and ongoing clinical trials reflect the industry's continuous pursuit of innovative medicines. The announced merger aligns with broader consolidation trends in the biotech industry, while the discussion of tariffs and government price controls highlights the significant regulatory and economic pressures faced by pharmaceutical companies globally.

Comparison to Industry Standards

• DANYELZA's 12-month event-free survival (EFS) rate of 36% in the osteosarcoma trial (Study 15-096) and 50% for patients with 4+ staining intensity GD2 expression, while missing the 40% endpoint, is considered compelling when compared to the typical standard of care EFS of approximately 20% reported in various published studies for this indication.

Corporate Governance

Legal Proceedings

• Donoghue vs. Y-mAbs Therapeutics, Inc., and Gad: A shareholder lawsuit alleging short swing profits against Mr. Thomas Gad. The Court affirmed dismissal of the claims against Mr. Gad on July 14, 2025, and the company considers the case closed.
• In re Y-mAbs Therapeutics, Inc. Securities Litigation: A putative class-action lawsuit alleging violations of U.S. federal securities laws. The lawsuit was resolved through a settlement where the company agreed to pay $19.65 million (net $3.625 million after insurance proceeds). The settlement was approved by the Court on October 28, 2024, and the case is considered closed.
• Hazelton vs. Y-mAbs Therapeutics Inc., and Gad, et al.: A purported stockholder lawsuit alleging excessive compensation for current and former board members. The case was settled, resulting in the cancellation of 60,000 stock options for non-employee directors, amendments to the Compensation Committee Charter, and a payment of $225,000 in attorneys' fees. The case is considered closed.

Related Party Transactions

• The company has ongoing license agreements with Memorial Sloan Kettering Cancer Center (MSK) and Massachusetts Institute of Technology (MIT) for intellectual property related to DANYELZA and the SADA PRIT Technology, which involve royalty and milestone payments.
• The company is obligated to pay MSK mid to high single-digit royalties based on annual net sales of licensed products under the MSK License and SADA License Agreement.
• The company is obligated to pay MSK and MIT certain clinical, regulatory, and sales-based milestone payments under the SADA License Agreement.
• The company recognized $500,000 in license revenue and a corresponding $50,000 in license royalties expense during the three and six months ended June 30, 2025, from a distribution partner in Israel, related to sales-based milestone achievements.

Stakeholder Impact

• Shareholders: The definitive merger agreement at $8.60 per share provides a clear valuation and potential cash exit, but also caps potential upside. There is a risk of share price decline if the merger fails to close. Past legal settlements have impacted shareholder value.
• Employees: A business realignment plan in January 2025 resulted in a workforce reduction of approximately 12%. The pending merger creates uncertainty about future roles and may affect employee retention.
• Customers/Patients: Continued commercialization of DANYELZA and ongoing clinical trials for DANYELZA and SADA PRIT aim to provide new and improved treatment options for cancer patients. However, the planned DANYELZA manufacturing transition in H2 2026 could lead to temporary production delays.
• Suppliers/Partners: Relationships with third-party contract manufacturers and distribution partners may be impacted by the DANYELZA manufacturing transition and the overall uncertainty surrounding the pending merger.
• Creditors: The company continues to incur net losses and use cash from operations, but the current cash position and the potential merger provide some financial stability.

Next Steps

• Purchaser will commence a cash tender offer for all outstanding shares of the company's common stock no later than August 19, 2025.
• The merger will be effected following the completion of the tender offer, subject to satisfaction or waiver of certain conditions.
• The DANYELZA Study 201 (confirmatory post-marketing clinical trial) is anticipated to be completed in 2028.
• The company is considering the advancement of a diagnostic tool for GD2 for potential pivotal trials in osteosarcoma or other GD2-related indications.
• The Beat Childhood Cancer Research consortium's Phase 2 trial for naxitamab in neuroblastoma will transition from a single-arm design to a comparative study with an external control arm.
• A multi-center Phase 1/2 study with MD Anderson Cancer Center for naxitamab in Triple Negative Breast Cancer is anticipated to start in the second half of 2025.
• The Dana-Farber Phase 1 clinical trial for naxitamab in relapsed or refractory neuroblastoma is expected to expand to at least 3 additional sites by the end of 2025, with primary completion estimated for the end of 2026.
• DANYELZA drug product manufacturing is expected to transition from Greenville, North Carolina, to Monza, Italy in the second half of 2026.
• The company will continue to assess the realizability of its deferred tax assets.
• The company is evaluating the impact of the One Big Beautiful Bill Act on its business operations.
• If the merger is not consummated, the company will need to obtain additional financing to fund future operations.

Key Dates

Recommendation

The definitive merger agreement at a fixed price of $8.60 per share effectively sets a ceiling for the stock's near-term trading range, as the market will price in the probability of the acquisition closing. For investors, the primary consideration shifts from operational performance to merger arbitrage. Given the fixed acquisition price, significant independent operational upside is limited, making a 'hold' recommendation appropriate for most investors who are not engaged in arbitrage strategies, as the stock's value is largely determined by the merger terms.

Keywords

Biopharmaceutical, Oncology, Cancer Treatment, Radioimmunotherapy, DANYELZA, Neuroblastoma, SADA PRIT, Merger, Acquisition, Clinical Trials, FDA Approval, SEC Filing, YMAB